Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Utility of PCD Diagnostics to Improve Clinical Care

NCT: NCT05889013 · RECRUITING

NCT IDNCT05889013
StatusRECRUITING
Start Date2023-10-17
Completion2028-12
SponsorConnecticut Children's Medical Center (OTHER)
First posted
Last updated

Brief Summary

This cross-sectional and longitudinal observational study is to gather data on the utility of tests that are used to make a diagnosis of primary ciliary dyskinesia (PCD). There is new testing available, called nasal nitric oxide testing, that non-invasively measures nitric oxide levels in the sinus cavity. Individuals with PCD characteristically have low levels, but this testing does not have extensive data from everyday clinical practice. The objective of this proposal is to improve the diagnostic approach to children and adults with clinical concerns for primary ciliary dyskinesia (PCD).

Frequently Asked Questions

What is Utility of PCD Diagnostics to Improve Clinical Care?

Utility of PCD Diagnostics to Improve Clinical Care is a clinical trial registered under NCT05889013. Current status: RECRUITING.

What is the status of NCT05889013?

The current status of NCT05889013 (Utility of PCD Diagnostics to Improve Clinical Care) is: RECRUITING.

When did Utility of PCD Diagnostics to Improve Clinical Care start?

Utility of PCD Diagnostics to Improve Clinical Care started on 2023-10-17.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑